INmune Bio (INMB)

• Market cap: $169M
• 1 day: -4.61%
• 5 days: -15.15%
• 1 month: -3.75%
• 3 months: 51.12%
• 6 months: 35.21%
• Year to date: 51.12%
• 1 year: -35.33%
• 5 years: 131.37%
• 10 years: -6.76%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

386% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 7

369% more call options, than puts

Call options by funds: $1.78M | Put options by funds: $379K

75% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 8

8% more funds holding

Funds holding: 66 [Q3] → 71 (+5) [Q4]

3.66% more ownership

Funds ownership: 24.17% [Q3] → 27.83% (+3.66%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

0% less capital invested

Capital invested by funds: $28.9M [Q3] → $28.8M (-$50.6K) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $23 209% upside
• Avg. target: $27 256% upside
• High target: $30 303% upside

2 analyst ratings

• positive: 2 100%
• neutral: 0 0%
• negative: 0 0%

Maxim Group Jason McCarthy 17% 1-year accuracy 6 / 36 met price target	303% upside $30	Buy Maintained	13 Feb 2025
Scotiabank George Farmer 27% 1-year accuracy 6 / 22 met price target	209% upside $23	Sector Outperform Maintained	11 Feb 2025